



ASX ANNOUNCEMENT

13 March 2020

CardieX Announces Expansion of Two Clinical Trials with Major Global Pharmaceutical Companies

CardieX Limited (ASX: CDX) (CardieX, the Company) is pleased to announce the expansion of two clinical trials this last week with existing customers AstraZeneca and Bayer for the provision of XCEL devices and data management services. Both these trials are being supported by CardieX subsidiary ATCOR Medical and provide for the lease of ATCOR's XCEL device as well as data management services for the full period of the trial.

ATCOR's XCEL device is the only FDA cleared device for measuring the central aortic waveform and reporting on associated clinical data in adult subjects. XCEL is used by clinicians, research institutions, and pharmaceutical companies in monitoring critical hemodynamic data during patient treatment and drug trials in multiple clinical settings and for multiple disease states.

AstraZeneca (OTCMKTS: AZNCF:\$USD60b) originally contracted ATCOR in October 2018 to provide clinical services and devices with a contract value of \$USD226,000. The total value of that contract and ongoing trial has now been increased to \$USD340,217 including the recent increase in contract value of \$USD75,760.

Bayer (OTCMKTS: BAYZF: \$USD15b) originally contracted ATCOR in December 2017 to provide clinical services and devices with a contract value of \$USD756,000. The total value of that contract and ongoing trial has now been increased to \$USD1.261M including the recent increase in contract value of \$USD75,426.

In addition, we are expecting further amendments in respect of ***additional existing trials as well as new trial contracts*** in the immediate future adding significant new incremental revenue to the Company for 2020.

All in, these new contracts and potential new trial services revenue in the immediate future support our revenue growth targets for 2020. As previously outlined to shareholders, management continues to drive forward on our 2020 target of an increase of 50% revenues for the 2020 year across all group divisions.

Craig Cooper
CEO & Managing Director

For more information please contact:

Investor Relations
Peter Taylor
peter@nwrcommunications.com.au



About CardieX

CardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related disorders.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

In September 2019 CardieX signed a joint development agreement with Mobvoi Information Technology Co. Ltd (Google's official Wear OS partner in China) to jointly develop an ecosystem of "smart heart" and other consumer health applications for the Google Wear OS platform in China based on CardieX subsidiary, ATCOR, software and algorithms.